% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Haebe:298221,
      author       = {S. Haebe and G. Schuebbe and P. Jurmeister and M. von
                      Bergwelt-Baildon$^*$ and C. B. Westphalen$^*$ and U. M.
                      Lauer and W. G. Kunz and M. Subklewe and O. Weigert$^*$},
      title        = {{A}dding checkpoint inhibitors to first-line chemotherapy
                      for {NUT} carcinoma patients.},
      journal      = {npj precision oncology},
      volume       = {9},
      number       = {1},
      issn         = {2397-768X},
      address      = {[London]},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2025-00228},
      pages        = {26},
      year         = {2025},
      abstract     = {Rare cancers present significant challenges in diagnosis,
                      treatment, and research, accounting for up to $25\%$ of
                      global cancer cases. Due to their rarity and atypical
                      presentations, they are often misdiagnosed, resulting in
                      late-stage detection and poor outcomes. Here, we describe a
                      patient case with advanced metastatic nasopharynx NUT
                      carcinoma, one of the rarest and most aggressive cancers. We
                      conducted a comprehensive analysis of this patient's tumor,
                      including Tumor Mutation Burden, Microsatellite Instability,
                      and genetic profiling to explore further putative druggable
                      targets. The tumor exhibited high PD-L1 expression and
                      showed a notable response to immune checkpoint inhibitors
                      when combined with platinum-based radio-chemotherapy. Our
                      findings indicate that checkpoint inhibitors could play a
                      critical role in treating NUT carcinoma, offering new
                      therapeutic avenues and hope for patients with this
                      challenging diagnosis. Whether PD-L1 expression may be a
                      useful predictor of immune checkpoint inhibitor efficacy
                      warrants further research.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39863772},
      pmc          = {pmc:PMC11762287},
      doi          = {10.1038/s41698-024-00768-7},
      url          = {https://inrepo02.dkfz.de/record/298221},
}